Lynparza® (olaparib) Receives Health Canada Approval for the Treatment of BRCA or ATM Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

October 13, 2020

Lynparza is the first targeted treatment approved in biomarker-selected prostate cancer validated by a Phase III trial

Read the full press release provided by AstraZeneca Canada Inc.